secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kiniksa Pharmaceuticals International, plc (KNSA)
CIK:        0001730430
Form:       8-K
Filed at:   2021-11-01T23:59:59+00:00
Accession:  0001104659-21-132088
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiniksa reports Q3 ARCALYST net revenue of $12.1M; net loss narrows to $30.5M
-----------------------------------------------------------------------------

- ARCALYST net revenue $12.1M in Q3 2021; Q4 2021 revenue guided to $16-17M.
- Net loss of $30.5M improved from $43.8M in Q3 2020; operating expenses $42.8M.
- Cash and investments $200.2M, no debt; cash expected to fund operations into 2023.
- Mavrilimumab Phase 3 in COVID-19 ARDS data expected Q1 2022; vixarelimab Phase 2b data in prurigo nodularis expected 2H 2022.
- Over 200 physicians prescribed ARCALYST for recurrent pericarditis since approval; >190M lives covered.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730430/000110465921132088/0001104659-21-132088-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730430/000110465921132088/tm2131179d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-132088

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer